Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05161195
Title Roll-over Study to Allow Continued Access to Ribociclib
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Novartis Pharmaceuticals

breast cancer


Fulvestrant + Ribociclib


Ribociclib + Tamoxifen

Goserelin + Ribociclib

Letrozole + Ribociclib

Anastrozole + Ribociclib

Age Groups: adult | senior
Covered Countries USA | ITA | ESP

No variant requirements are available.